Article
Synthetic gene circuits that selectively target RAS-driven cancers
2024-11-11
Abstract excerpt
Therapies targeting mutated RAS, the most frequently mutated oncogene in human cancers, could benefit millions of patients. Recently approved RAS inhibitors represent a breakthrough, but are limited to a specific KRAS G12C mutation and prone to resistance. Synthetic gene circuits offer a promising alternative by sensing and integrating cancer-specific biomolecular inputs, including mutated RAS, to selectively exp...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 3e577ae8-18b2-5d8a-a003-ec7cc573fdad
- DOI
- 10.1101/2024.11.11.622942
